Monte Rosa Therapeutics, Inc. Variable Lease, Cost
Monte Rosa Therapeutics, Inc. (GLUE) reported Variable Lease, Cost of $644.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. variable lease, cost for the quarter ending 2026-06-30 was $644.00K, a 130.00% increase year-over-year.
- Monte Rosa Therapeutics, Inc. variable lease, cost for the quarter ending 2026-03-31 was $758.00K, a 11.03% decline year-over-year.
- Monte Rosa Therapeutics, Inc. variable lease, cost for the quarter ending 2025-12-31 was $769.00K, a 15.59% decline year-over-year.
- Monte Rosa Therapeutics, Inc. variable lease, cost for the quarter ending 2025-09-30 was $745.00K, a 18.31% decline year-over-year.
- Monte Rosa Therapeutics, Inc. variable lease, cost for fiscal 2025 was $2.65M, a 33.08% decline from fiscal 2024.
- Monte Rosa Therapeutics, Inc. variable lease, cost for fiscal 2024 was $3.95M, a 70.65% increase from fiscal 2023.
- Monte Rosa Therapeutics, Inc. variable lease, cost for fiscal 2023 was $2.32M, a 22.08% increase from fiscal 2022.
- Monte Rosa Therapeutics, Inc. variable lease, cost for fiscal 2022 was $1.90M.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $644.00K 10-Q · filed 2026-08-06 | $1.40M 10-Q · filed 2026-08-06 | $2.17M derived: sum of 3 quarters · filed 2026-08-06 | $2.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $758.00K 10-Q · filed 2026-05-07 | $1.53M derived: sum of 2 quarters · filed 2026-05-07 | $2.27M derived: sum of 3 quarters · filed 2026-05-07 | $2.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $769.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.51M derived: sum of 2 quarters · filed 2026-03-17 | $1.79M derived: sum of 3 quarters · filed 2026-08-06 | $2.65M 10-K · filed 2026-03-17 |
| 2025-09-30 | $745.00K 10-Q · filed 2025-11-06 | $1.02M derived: sum of 2 quarters · filed 2026-08-06 | $1.88M 10-Q · filed 2025-11-06 | $2.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $280.00K 10-Q · filed 2026-08-06 | $1.13M 10-Q · filed 2026-08-06 | $2.04M derived: sum of 3 quarters · filed 2026-08-06 | $2.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $852.00K 10-Q · filed 2026-05-07 | $1.76M derived: sum of 2 quarters · filed 2026-05-07 | $2.67M derived: sum of 3 quarters · filed 2026-05-07 | $3.93M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $911.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.82M derived: sum of 2 quarters · filed 2026-03-17 | $3.08M derived: sum of 3 quarters · filed 2026-03-17 | $3.95M 10-K · filed 2026-03-17 |
| 2024-09-30 | $912.00K 10-Q · filed 2025-11-06 | $2.16M derived: sum of 2 quarters · filed 2025-11-06 | $3.04M 10-Q · filed 2025-11-06 | $3.66M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.25M 10-Q · filed 2025-08-07 | $2.13M 10-Q · filed 2025-08-07 | $2.75M derived: sum of 3 quarters · filed 2025-08-07 | $3.32M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $879.00K 10-Q · filed 2025-05-08 | $1.50M derived: sum of 2 quarters · filed 2025-05-08 | $2.07M derived: sum of 3 quarters · filed 2025-05-08 | $2.67M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $617.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $1.19M derived: sum of 2 quarters · filed 2025-03-20 | $1.79M derived: sum of 3 quarters · filed 2025-03-20 | $2.32M 10-K · filed 2025-03-20 |
| 2023-09-30 | $572.00K 10-Q · filed 2024-11-07 | $1.17M derived: sum of 2 quarters · filed 2024-11-07 | $1.70M 10-Q · filed 2024-11-07 | $2.47M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $597.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.13M 10-Q · filed 2024-08-08 | $1.90M derived: sum of 3 quarters · filed 2024-08-08 | $2.41M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $531.00K 10-Q · filed 2024-05-09 | $1.30M derived: sum of 2 quarters · filed 2024-05-09 | $1.81M derived: sum of 3 quarters · filed 2024-05-09 | $2.31M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $770.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.28M derived: sum of 2 quarters · filed 2024-03-14 | $1.78M derived: sum of 3 quarters · filed 2024-03-14 | $1.90M 10-K · filed 2024-03-14 |
| 2022-09-30 | $511.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.01M derived: sum of 2 quarters · filed 2023-11-09 | $1.13M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $499.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $617.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $118.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |